Nexstim Plc

Helsinki Stock Exchange NXTMH.HE

Nexstim Plc Price to Sales Ratio (P/S) on January 14, 2025: 7.84

Nexstim Plc Price to Sales Ratio (P/S) is 7.84 on January 14, 2025, a 200.81% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Nexstim Plc 52-week high Price to Sales Ratio (P/S) is 8.62 on January 07, 2025, which is 9.84% above the current Price to Sales Ratio (P/S).
Nexstim Plc 52-week low Price to Sales Ratio (P/S) is 2.10 on April 16, 2024, which is -73.21% below the current Price to Sales Ratio (P/S).
Nexstim Plc average Price to Sales Ratio (P/S) for the last 52 weeks is 3.56.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Helsinki Stock Exchange: NXTMH.HE

Nexstim Plc

CEO	Mr. Mikko Karvinen
IPO Date	Nov. 14, 2014
Location	Finland
Headquarters	ElimAeenkatu 9 B
Employees	39
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Nexstim Plc, a medical technology company, engages in the development and marketing of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally. The company's proprietary SmartFocus technology with 3D navigation is the navigated transcranial magnetic stimulation (TMS) approach that is used for therapeutic and diagnostic applications. It offers NBT system, a navigated brain therapy system for the treatment of major depression and chronic neuropathic pain; and NBS system, a navigated brain stimulation system for pre-surgical mapping of the speech and motor cortices of the brain. The company primarily sells its NBS systems to universities and teaching hospitals. Nexstim Plc was founded in 2000 and is headquartered in Helsinki, Finland.

Key trends

Past 5 years